Clinical Trials Update from NCI, May 23, 2017

Clinical Trials Update from NCI, May 23, 2017

Clinical Trials
Updates from the National Cancer Institute
Clinical Trials News
		Facebook Live Event on Advanced Melanoma On May 25, 2017 at 12:00 p.m. ET, NCI will host a Facebook Live event about Advanced Melanoma Research and Treatment. Subject matter experts from NCI and the University of Chicago will discuss research and treatment for advanced stage melanoma with advocate Jamie Troil-Goldfarb, a clinical trial participant and stage IV melanoma survivor.
Collection of Patient-Reported Outcomes Feasible in Cancer Clinical Trials A new study conducted in collaboration with a cooperative group chemoradiotherapy clinical trial finds that most patients participating in the multicenter trial were willing and able to self report symptomatic adverse events using NCI’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
		Find NCI-Supported Clinical Trials Use our search form to find a clinical trial or other research study that may be right for you or a loved one.
Clinical Trials Information for Patients and Caregivers
What Are Clinical Trials? Basic information that explains what clinical trials are and why they are critical to making progress against cancer.
Use of Placebos Placebos are rarely used in cancer clinical trials. Learn about the limited role that placebos may play in some clinical trials for cancer.
NCI-Supported Clinical Trials that Are Recruiting Patients
Ropidoxuridine and Whole Brain Radiation Therapy for Patients with Brain Metastases This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy to treat patients with cancer that has spread to the brain.
Vaccine Therapy and Immunotherapy for Men with Prostate Cancer This phase I trial studies the side effects of a therapeutic vaccine combined with nivolumab with or without ipilimumab in treating men with prostate cancer.
Tocilizumab with or without Antiviral Therapy for Patients with KSHV-Associated Multicentric Castleman Disease This pilot phase II trial studies tocilizumab in treating patients with Kaposi sarcoma herpes virus (KSHV)-associated multicentric Castleman disease, a type of lymphoproliferative disease similar to lymphoma.